Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $148.9 million.

  • Artiva Biotherapeutics' Liabilities and Shareholders Equity fell 3401.39% to $148.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.1 million, marking a year-over-year increase of 7684.66%. This contributed to the annual value of $209.6 million for FY2024, which is 9938.45% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Liabilities and Shareholders Equity of $148.9 million as of Q3 2025, which was down 3401.39% from $169.4 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Liabilities and Shareholders Equity registered a high of $225.6 million during Q3 2024, and its lowest value of $75.9 million during Q2 2024.
  • For the 3-year period, Artiva Biotherapeutics' Liabilities and Shareholders Equity averaged around $160.8 million, with its median value being $169.4 million (2025).
  • The largest annual percentage gain for Artiva Biotherapeutics' Liabilities and Shareholders Equity in the last 5 years was 12314.13% (2025), contrasted with its biggest fall of 3401.39% (2025).
  • Artiva Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $105.1 million in 2023, then skyrocketed by 99.38% to $209.6 million in 2024, then dropped by 28.97% to $148.9 million in 2025.
  • Its last three reported values are $148.9 million in Q3 2025, $169.4 million for Q2 2025, and $191.3 million during Q1 2025.